ID proteins regulate diverse aspects of cancer progression and provide novel therapeutic opportunities

Molecular Therapy

Volumn 22, Issue 8, 2014, Pages 1407-1415

  Nair, Radhika ^a,b   Teo, Wee Siang ^a,b   Mittal, Vivek ^c   Swarbrick, Alexander ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION 3; INHIBITOR OF DIFFERENTIATION 4; INHIBITOR OF DIFFERENTIATION PROTEIN; PEPTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CANNABIDIOL; OXALIPLATIN; THROMBOSPONDIN 1;

ANGIOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL HETEROGENEITY; CELL MOTILITY; CELL PROLIFERATION; CELL RENEWAL; CELL SUBPOPULATION; DOWN REGULATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE OVEREXPRESSION; GROWTH REGULATION; HUMAN; ID GENE; MALIGNANT TRANSFORMATION; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; TUMOR MICROENVIRONMENT; UPREGULATION; CANCER PROGNOSIS; ENDOTHELIAL PROGENITOR CELL; GLIOMA; OVARY CANCER; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; METABOLISM; NEOPLASM; PATHOLOGY;

HUMANS; INHIBITOR OF DIFFERENTIATION PROTEINS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 84905496932     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.83     Document Type: Review

References (144)

1. Nam, HS and Benezra, R (2009). High levels of Id1 expression define B1 type adult neural stem cells. Cell Stem Cell 5: 515-526.
2. Jankovic, V, Ciarrocchi, A, Boccuni, P, DeBlasio, T, Benezra, R and Nimer, SD (2007). Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. Proc Natl Acad Sci USA 104: 1260-1265.
3. Perry, SS, Zhao, Y, Nie, L, Cochrane, SW, Huang, Z and Sun, XH (2007). Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance. Blood 110: 2351-2360.
4. Romero-Lanman, EE, Pavlovic, S, Amlani, B, Chin, Y and Benezra, R (2012). Id1 maintains embryonic stem cell self-renewal by up-regulation of Nanog and repression of Brachyury expression. Stem Cells Dev 21: 384-393.
5. Suh, HC, Ji, M, Gooya, J, Lee, M, Klarmann, KD and Keller, JR (2009). Cellnonautonomous function of Id1 in the hematopoietic progenitor cell niche. Blood 114: 1186-1195.
6. Niola, F, Zhao, X, Singh, D, Castano, A, Sullivan, R, Lauria, M et al. (2012). Id proteins synchronize stemness and anchorage to the niche of neural stem cells. Nat Cell Biol 14: 477-487.
7. Lim, RW and Wu, JM (2005). Molecular mechanisms regulating expression and function of transcription regulator inhibitor of differentiation 3. Acta Pharmacol Sin 26: 1409-1420.
8. Norton, JD (2000). ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 113: 3897-3905.
9. Biggs, J, Murphy, EV and Israel, MA (1992). A human Id-like helix-loop-helix protein expressed during early development. Proc Natl Acad Sci USA 89: 1512-1516.
10. Riechmann, V, van Crüchten, I and Sablitzky, F (1994). The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3. Nucleic Acids Res 22: 749-755.
11. Sun, XH, Copeland, NG, Jenkins, NA and Baltimore, D (1991). Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol 11: 5603-5611.
12. Benezra, R, Davis, RL, Lockshon, D, Turner, DL and Weintraub, H (1990). The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61: 49-59.
13. Lasorella, A, Iavarone, A and Israel, MA (1996). Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol 16: 2570-2578.
14. Ohtani, N, Zebedee, Z, Huot, TJ, Stinson, JA, Sugimoto, M, Ohashi, Y et al. (2001). Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409: 1067-1070.
15. Fontemaggi, G, Dell'Orso, S, Trisciuoglio, D, Shay, T, Melucci, E, Fazi, F et al. (2009). The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16: 1086-1093.
16. Jen, Y, Manova, K and Benezra, R (1997). Each member of the Id gene family exhibits a unique expression pattern in mouse gastrulation and neurogenesis. Dev Dyn 208: 92-106.
17. Perk, J, Gil-Bazo, I, Chin, Y, de Candia, P, Chen, JJ, Zhao, Y et al. (2006). Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res 66: 10870-10877.
18. Kowanetz, M, Valcourt, U, Bergström, R, Heldin, CH and Moustakas, A (2004). Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol 24: 4241-4254.
19. Kang, Y, Chen, CR and Massagué, J (2003). A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol Cell 11: 915-926.
20. Lin, CQ, Singh, J, Murata, K, Itahana, Y, Parrinello, S, Liang, SH et al. (2000). A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 60: 1332-1340.
21. Tam, WF, Gu, TL, Chen, J, Lee, BH, Bullinger, L, Fröhling, S et al. (2008). Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood 112: 1981-1992.
22. Bain, G, Cravatt, CB, Loomans, C, Alberola-Ila, J, Hedrick, SM and Murre, C (2001). Regulation of the helix-loop-helix proteins, E2A and Id3, by the Ras-ERK MAPK cascade. Nat Immunol 2: 165-171.
23. Lasorella, A, Noseda, M, Beyna, M, Yokota, Y and Iavarone, A (2000). Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407: 592-598.
24. Lasorella, A, Stegmüller, J, Guardavaccaro, D, Liu, G, Carro, MS, Rothschild, G et al. (2006). Degradation of Id2 by the anaphase-promoting complex couples cell cycle exit and axonal growth. Nature 442: 471-474.
25. Williams, SA, Maecker, HL, French, DM, Liu, J, Gregg, A, Silverstein, LB et al. (2011). USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 146: 918-930.
26. Gupta, GP, Perk, J, Acharyya, S, de Candia, P, Mittal, V, Todorova-Manova, K et al. (2007). ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA 104: 19506-19511.
27. Anido, J, Sáez-Borderías, A, Gonzàlez-Juncà, A, Rodón, L, Folch, G, Carmona, MA et al. (2010). TGF-â Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell 18: 655-668.
28. Love, C, Sun, Z, Jima, D, Li, G, Zhang, J, Miles, R et al. (2012). The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 44: 1321-1325.
29. Richter, J, Schlesner, M, Hoffmann, S, Kreuz, M, Leich, E, Burkhardt, B et al. ICGC MMML-Seq Project. (2012). Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44: 1316-1320.
30. Schmitz, R, Young, RM, Ceribelli, M, Jhavar, S, Xiao, W, Zhang, M et al. (2012). Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490: 116-120.
31. Yu, L, Liu, C, Vandeusen, J, Becknell, B, Dai, Z, Wu, YZ et al. (2005). Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 37: 265-274.
32. Chen, SS, Claus, R, Lucas, DM, Yu, L, Qian, J, Ruppert, AS et al. (2011). Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood 117: 862-871.
33. Ren, Y, Cheung, HW, von Maltzhan, G, Agrawal, A, Cowley, GS, Weir, BA et al. (2012). Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4. Sci Transl Med 4: 147ra112.
34. Turner, N, Tutt, A and Ashworth, A (2004). Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4: 814-819.
35. Beger, C, Pierce, LN, Kruger, M, Marcusson, EG, Robbins, JM, Welcsh, P et al. (2001). Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-librarybased inverse genomics approach. Proc Natl Acad Sci USA 98: 130-135.
36. Welcsh, PL, Lee, MK, Gonzalez-Hernandez, RM, Black, DJ, Mahadevappa, M, Swisher, EM et al. (2002). BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. Proc Natl Acad Sci USA 99: 7560-7565.
37. Gautschi, O, Tepper, CG, Purnell, PR, Izumiya, Y, Evans, CP, Green, TP et al. (2008). Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res 68: 2250-2258.
38. Birkenkamp, KU, Essafi, A, van der Vos, KE, da Costa, M, Hui, RC, Holstege, F et al. (2007). FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1. J Biol Chem 282: 2211-2220.
39. Paolella, BR, Havrda, MC, Mantani, A, Wray, CM, Zhang, Z and Israel, MA (2011). p53 directly represses Id2 to inhibit the proliferation of neural progenitor cells. Stem Cells 29: 1090-1101.
40. Kang, Y, Siegel, PM, Shu, W, Drobnjak, M, Kakonen, SM, Cordón-Cardo, C et al. (2003). A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
41. Perk, J, Iavarone, A and Benezra, R (2005). Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 5: 603-614.
42. Swarbrick, A, Akerfeldt, MC, Lee, CS, Sergio, CM, Caldon, CE, Hunter, LJ et al. (2005). Regulation of cyclin expression and cell cycle progression in breast epithelial cells by the helix-loop-helix protein Id1. Oncogene 24: 381-389.
43. Ling, MT, Wang, X, Ouyang, XS, Xu, K, Tsao, SW and Wong, YC (2003). Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 22: 4498-4508.
44. Li, B, Tsao, SW, Li, YY, Wang, X, Ling, MT, Wong, YC et al. (2009). Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int J Cancer 125: 2576-2585.
45. Lin, J, Guan, Z, Wang, C, Feng, L, Zheng, Y, Caicedo, E et al. (2010). Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways. Clin Cancer Res 16: 77-87.
46. Lee, JY, Kang, MB, Jang, SH, Qian, T, Kim, HJ, Kim, CH et al. (2009). Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition. Oncogene 28: 824-831.
47. Kim, H, Chung, H, Kim, HJ, Lee, JY, Oh, MY, Kim, Y et al. (2008). Id-1 regulates Bcl-2 and Bax expression through p53 and NF-kappaB in MCF-7 breast cancer cells. Breast Cancer Res Treat 112: 287-296.
48. Tang, J, Gordon, GM, Nickoloff, BJ and Foreman, KE (2002). The helix-loop-helix protein id-1 delays onset of replicative senescence in human endothelial cells. Lab Invest 82: 1073-1079.
49. Alani, RM, Young, AZ and Shifflett, CB (2001). Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci USA 98: 7812-7816.
50. Nickoloff, BJ, Chaturvedi, V, Bacon, P, Qin, JZ, Denning, MF and Diaz, MO (2000). Id-1 delays senescence but does not immortalize keratinocytes. J Biol Chem 275: 27501-27504.
51. Alani, RM, Hasskarl, J, Grace, M, Hernandez, MC, Israel, MA and Münger, K (1999). Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc Natl Acad Sci USA 96: 9637-9641.
52. Visvader, JE and Lindeman, GJ (2010). Stem cells and cancer - the promise and puzzles. Mol Oncol 4: 369-372.
53. Chan, AS, Jensen, KK, Skokos, D, Doty, S, Lederman, HK, Kaplan, RN et al. (2009). Id1 represses osteoclast-dependent transcription and affects bone formation and hematopoiesis. PLoS One 4: e7955.
54. Gilbertson, RJ and Rich, JN (2007). Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 7: 733-736.
55. Vandeputte, DA, Troost, D, Leenstra, S, Ijlst-Keizers, H, Ramkema, M, Bosch, DA et al. (2002). Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia 38: 329-338.
56. Gargiulo, G, Cesaroni, M, Serresi, M, de Vries, N, Hulsman, D, Bruggeman, SW et al. (2013). In vivo RNAi screen for BMI1 targets identifies TGF-â/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. Cancer Cell 23: 660-676.
57. Niola, F, Zhao, X, Singh, D, Sullivan, R, Castano, A, Verrico, A et al. (2013). Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J Clin Invest 123: 405-417.
58. Soroceanu, L, Murase, R, Limbad, C, Singer, E, Allison, J, Adrados, I et al. (2013). Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target. Cancer Res 73: 1559-1569.
59. Barrett, LE, Granot, Z, Coker, C, Iavarone, A, Hambardzumyan, D, Holland, EC et al. (2012). Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell 21: 11-24.
60. Jin, X, Yin, J, Kim, SH, Sohn, YW, Beck, S, Lim, YC et al. (2011). EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res 71: 7125-7134.
61. Jeon, HM, Jin, X, Lee, JS, Oh, SY, Sohn, YW, Park, HJ et al. (2008). Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev 22: 2028-2033.
62. Jeon, HM, Sohn, YW, Oh, SY, Oh, SY, Kim, SH, Beck, S et al. (2011). ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*- mediated suppression of SOX2. Cancer Res 71: 3410-3421.
63. Swarbrick, A, Roy, E, Allen, T and Bishop, JM (2008). Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci USA 105: 5402-5407.
64. Stankic, M, Pavlovic, S, Chin, Y, Brogi, E, Padua, D, Norton, L et al. (2013). TGF-â-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymalto- epithelial transition. Cell Rep 5: 1228-1242.
65. O'Brien, CA, Kreso, A, Ryan, P, Hermans, KG, Gibson, L, Wang, Y et al. (2012). ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 21: 777-792.
66. Klein, CA (2009). Parallel progression of primary tumours and metastases. Nat Rev Cancer 9: 302-312.
67. Minn, AJ, Gupta, GP, Siegel, PM, Bos, PD, Shu, W, Giri, DD et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
68. Fong, S, Itahana, Y, Sumida, T, Singh, J, Coppe, JP, Liu, Y et al. (2003). Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci USA 100: 13543-13548.
69. Gumireddy, K, Li, A, Gimotty, PA, Klein-Szanto, AJ, Showe, LC, Katsaros, D et al. (2009). KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 11: 1297-1304.
70. Tsuchiya, T, Okaji, Y, Tsuno, NH, Sakurai, D, Tsuchiya, N, Kawai, K et al. (2005). Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer. Cancer Sci 96: 784-790.
71. Shuno, Y, Tsuno, NH, Okaji, Y, Tsuchiya, T, Sakurai, D, Nishikawa, T et al. (2010). Id1/ Id3 knockdown inhibits metastatic potential of pancreatic cancer. J Surg Res 161: 76-82.
72. Mani, SA, Guo, W, Liao, MJ, Eaton, EN, Ayyanan, A, Zhou, AY et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
73. Morel, AP, Lièvre, M, Thomas, C, Hinkal, G, Ansieau, S and Puisieux, A (2008). Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 3: e2888.
74. Thiery, JP, Acloque, H, Huang, RY and Nieto, MA (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139: 871-890.
75. Zhang, X, Ling, MT, Wang, Q, Lau, CK, Leung, SC, Lee, TK et al. (2007). Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells. J Biol Chem 282: 33284-33294.
76. Cheung, PY, Yip, YL, Tsao, SW, Ching, YP and Cheung, AL (2011). Id-1 induces cell invasiveness in immortalized epithelial cells by regulating cadherin switching and Rho GTPases. J Cell Biochem 112: 157-168.
77. Li, Y, Yang, J, Luo, JH, Dedhar, S and Liu, Y (2007). Tubular epithelial cell dedifferentiation is driven by the helix-loop-helix transcriptional inhibitor Id1. J Am Soc Nephrol 18: 449-460.
78. Egeblad, M and Werb, Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
79. Valastyan, S and Weinberg, RA (2011). Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275-292.
80. Desprez, PY, Lin, CQ, Thomasset, N, Sympson, CJ, Bissell, MJ and Campisi, J (1998). A novel pathway for mammary epithelial cell invasion induced by the helix-loop-helix protein Id-1. Mol Cell Biol 18: 4577-4588.
81. Coppe, JP, Itahana, Y, Moore, DH, Bennington, JL and Desprez, PY (2004). Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res 10: 2044-2051.
82. Nieborowska-Skorska, M, Hoser, G, Rink, L, Malecki, M, Kossev, P, Wasik, MA et al. (2006). Id1 transcription inhibitor-matrix metalloproteinase 9 axis enhances invasiveness of the breakpoint cluster region/abelson tyrosine kinase-transformed leukemia cells. Cancer Res 66: 4108-4116.
83. Brabletz, T (2012). To differentiate or not-routes towards metastasis. Nat Rev Cancer 12: 425-436.
84. Ghajar, CM, Peinado, H, Mori, H, Matei, IR, Evason, KJ, Brazier, H et al. (2013). The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 15: 807-817.
85. Volpert, OV, Pili, R, Sikder, HA, Nelius, T, Zaichuk, T, Morris, C et al. (2002). Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2: 473-483.
86. Straume, O and Akslen, LA (2005). Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer 93: 933-938.
87. Kalas, W, Yu, JL, Milsom, C, Rosenfeld, J, Benezra, R, Bornstein, P et al. (2005). Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res 65: 8878-8886.
88. Martini, M, Cenci, T, D'Alessandris, GQ, Cesarini, V, Cocomazzi, A, Ricci-Vitiani, L et al. (2013). Epigenetic silencing of Id4 identifies a glioblastoma subgroup with a better prognosis as a consequence of an inhibition of angiogenesis. Cancer 119: 1004-1012.
89. Korchynskyi, O and ten Dijke, P (2002). Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277: 4883-4891.
90. López-Rovira, T, Chalaux, E, Massagué, J, Rosa, JL and Ventura, F (2002). Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J Biol Chem 277: 3176-3185.
91. Scharpfenecker, M, van Dinther, M, Liu, Z, van Bezooijen, RL, Zhao, Q, Pukac, L et al. (2007). BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 120(Pt 6): 964-972.
92. David, L, Mallet, C, Mazerbourg, S, Feige, JJ and Bailly, S (2007). Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961.
93. Tanaka, A, Itoh, F, Nishiyama, K, Takezawa, T, Kurihara, H, Itoh, S et al. (2010). Inhibition of endothelial cell activation by bHLH protein E2-2 and its impairment of angiogenesis. Blood 115: 4138-4147.
94. Mechtcheriakova, D, Schabbauer, G, Lucerna, M, Clauss, M, De Martin R, Binder, BR et al. (2001). Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 15: 230-242.
95. Mechtcheriakova, D, Wlachos, A, Holzmüller, H, Binder, BR and Hofer, E (1999). Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 93: 3811-3823.
96. Kim, HJ, Chung, H, Yoo, YG, Kim, H, Lee, JY, Lee, MO et al. (2007). Inhibitor of DNA binding 1 activates vascular endothelial growth factor through enhancing the stability and activity of hypoxia-inducible factor-1alpha. Mol Cancer Res 5: 321-329.
97. Lasorella, A, Rothschild, G, Yokota, Y, Russell, RG and Iavarone, A (2005). Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. Mol Cell Biol 25: 3563-3574.
98. Fraidenraich, D, Stillwell, E, Romero, E, Wilkes, D, Manova, K, Basson, CT et al. (2004). Rescue of cardiac defects in id knockout embryos by injection of embryonic stem cells. Science 306: 247-252.
99. Lyden, D, Young, AZ, Zagzag, D, Yan, W, Gerald, W, O'Reilly, R et al. (1999). Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401: 670-677.
100. Ruzinova, MB, Schoer, RA, Gerald, W, Egan, JE, Pandolfi, PP, Rafii, S et al. (2003). Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4: 277-289.
101. Li, H, Gerald, WL and Benezra, R (2004). Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res 64: 6137-6143.
102. de Candia, P, Solit, DB, Giri, D, Brogi, E, Siegel, PM, Olshen, AB et al. (2003). Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci USA 100: 12337-12342.
103. Lyden, D, Hattori, K, Dias, S, Costa, C, Blaikie, P, Butros, L et al. (2001). Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7: 1194-1201.
104. Gao, D, Nolan, DJ, Mellick, AS, Bambino, K, McDonnell, K and Mittal, V (2008). Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 319: 195-198.
105. Kerbel, RS, Benezra, R, Lyden, DC, Hattori, K, Heissig, B, Nolan, DJ et al. (2008). Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci USA 105: E54; author reply E55.
106. Nolan, DJ, Ciarrocchi, A, Mellick, AS, Jaggi, JS, Bambino, K, Gupta, S et al. (2007). Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 21: 1546-1558.
107. Mellick, AS, Plummer, PN, Nolan, DJ, Gao, D, Bambino, K, Hahn, M et al. (2010). Using the transcription factor inhibitor of DNA binding 1 to selectively target endothelial progenitor cells offers novel strategies to inhibit tumor angiogenesis and growth. Cancer Res 70: 7273-7282.
108. Su, Y, Zheng, L, Wang, Q, Bao, J, Cai, Z and Liu, A (2010). The PI3K/Akt pathway upregulates Id1 and integrin á4 to enhance recruitment of human ovarian cancer endothelial progenitor cells. BMC Cancer 10: 459.
109. Yan, W, Young, AZ, Soares, VC, Kelley, R, Benezra, R and Zhuang, Y (1997). High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol Cell Biol 17: 7317-7327.
110. Ciarrocchi, A, Jankovic, V, Shaked, Y, Nolan, DJ, Mittal, V, Kerbel, RS et al. (2007). Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS One 2: e1338.
111. Li, W, Wang, H, Kuang, CY, Zhu, JK, Yu, Y, Qin, ZX et al. (2012). An essential role for the Id1/PI3K/Akt/NFkB/survivin signalling pathway in promoting the proliferation of endothelial progenitor cells in vitro. Mol Cell Biochem 363: 135-145.
112. Mern, DS, Hoppe-Seyler, K, Hoppe-Seyler, F, Hasskarl, J and Burwinkel, B (2010). Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells. Breast Cancer Res Treat 124: 623-633.
113. Mern, DS, Hasskarl, J and Burwinkel, B (2010). Inhibition of Id proteins by a peptide aptamer induces cell-cycle arrest and apoptosis in ovarian cancer cells. Br J Cancer 103: 1237-1244.
114. Mistry, H, Hsieh, G, Buhrlage, SJ, Huang, M, Park, E, Cuny, GD et al. (2013). Smallmolecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther 12: 2651-2662.
115. Shaked, Y, Henke, E, Roodhart, JM, Mancuso, P, Langenberg, MH, Colleoni, M et al. (2008). Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273.
116. Henke, E, Perk, J, Vider, J, de Candia, P, Chin, Y, Solit, DB et al. (2008). Peptideconjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 26: 91-100.
117. Ding, Y, Wang, G, Ling, MT, Wong, YC, Li, X, Na, Y et al. (2006). Significance of Id-1 up-regulation and its association with EGFR in bladder cancer cell invasion. Int J Oncol 28: 847-854.
118. Olmeda, D, Moreno-Bueno, G, Flores, JM, Fabra, A, Portillo, F and Cano, A (2007). SNAI1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res 67: 11721-11731.
119. Tobin, NP, Sims, AH, Lundgren, KL, Lehn, S and Landberg, G (2011). Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer 11: 417.
120. Wilson, JW, Deed, RW, Inoue, T, Balzi, M, Becciolini, A, Faraoni, P et al. (2001). Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index. Cancer Res 61: 8803-8810.
121. Yang, HY, Liu, HL, Liu, GY, Zhu, H, Meng, QW, Qu, LD et al. (2011). Expression and prognostic values of Id-1 and Id-3 in gastric adenocarcinoma. J Surg Res 167: 258-266.
122. Iwatsuki, M, Fukagawa, T, Mimori, K, Nakanishi, H, Ito, S, Ishii, H et al. (2009). Bone marrow and peripheral blood expression of ID1 in human gastric carcinoma patients is a bona fide indicator of lymph node and peritoneal metastasis. Br J Cancer 100: 1937-1942.
123. Sun, W, Guo, MM, Han, P, Lin, JZ, Liang, FY, Tan, GM et al. (2012). Id-1 and the p65 subunit of NF-êB promote migration of nasopharyngeal carcinoma cells and are correlated with poor prognosis. Carcinogenesis 33: 810-817.
124. Li, X, Zhang, Z, Xin, D, Chua, CW, Wong, YC, Leung, SC et al. (2007). Prognostic significance of Id-1 and its association with EGFR in renal cell cancer. Histopathology 50: 484-490.
125. Bhattacharya, R, Kowalski, J, Larson, AR, Brock, M and Alani, RM (2010). Id1 promotes tumor cell migration in nonsmall cell lung cancers. J Oncol 2010: 856105.
126. Pillai, S, Rizwani, W, Li, X, Rawal, B, Nair, S, Schell, MJ et al. (2011). ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol 31: 3052-3067.
127. Castañon, E, Bosch-Barrera, J, López, I, Collado, V, Moreno, M, López-Picazo, JM et al. (2013). Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 nonsmall cell lung cancer patients treated with definitive chemoradiotherapy. J Transl Med 11: 13.
128. Ponz-Sarvisé, M, Nguewa, PA, Pajares, MJ, Agorreta, J, Lozano, MD, Redrado, M et al. (2011). Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. Clin Cancer Res 17: 4155-4166.
129. Ding, R, Han, S, Lu, Y, Guo, C, Xie, H, Zhang, N et al. (2010). Overexpressed Id-1 is associated with patient prognosis and HBx expression in hepatitis B virus-related hepatocellular carcinoma. Cancer Biol Ther 10: 299-307.
130. Matsuda, Y, Yamagiwa, S, Takamura, M, Honda, Y, Ishimoto, Y, Ichida, T et al. (2005). Overexpressed Id-1 is associated with a high risk of hepatocellular carcinoma development in patients with cirrhosis without transcriptional repression of p16. Cancer 104: 1037-1044.
131. Luo, KJ, Wen, J, Xie, X, Fu, JH, Luo, RZ, Wu, QL et al. (2012). Prognostic relevance of Id-1 expression in patients with resectable esophageal squamous cell carcinoma. Ann Thorac Surg 93: 1682-1688.
132. Schindl, M, Schoppmann, SF, Ströbel, T, Heinzl, H, Leisser, C, Horvat, R et al. (2003). Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res 9: 779-785.
133. Maruyama, H, Kleeff, J, Wildi, S, Friess, H, Büchler, MW, Israel, MA et al. (1999). Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol 155: 815-822.
134. Sharma, P, Patel, D and Chaudhary, J (2012). Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B. Cancer Med 1: 187-197.
135. Ciarrocchi, A, Piana, S, Valcavi, R, Gardini, G and Casali, B (2011). Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells. Eur J Cancer 47: 934-945.
136. Kebebew, E, Peng, M, Treseler, PA, Clark, OH, Duh, QY, Ginzinger, D et al. (2004). Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells. J Clin Endocrinol Metab 89: 6105-6111.
137. Stighall, M, Manetopoulos, C, Axelson, H and Landberg, G (2005). High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. Int J Cancer 115: 403-411.
138. Renné, C, Martin-Subero, JI, Eickernjäger, M, Hansmann, ML, Küppers, R, Siebert, R et al. (2006). Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am J Pathol 169: 655-664.
139. Kleeff, J, Ishiwata, T, Friess, H, Büchler, MW, Israel, MA and Korc, M (1998). The helixloop- helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res 58: 3769-3772.
140. Lee, SH, Hao, E, Kiselyuk, A, Shapiro, J, Shields, DJ, Lowy, A et al. (2011). The Id3/E47 axis mediates cell-cycle control in human pancreatic ducts and adenocarcinoma. Mol Cancer Res 9: 782-790.
141. Zeng, W, Rushing, EJ, Hartmann, DP and Azumi, N (2010). Increased inhibitor of differentiation 4 (id4) expression in glioblastoma: a tissue microarray study. J Cancer 1: 1-5.
142. Umetani, N, Mori, T, Koyanagi, K, Shinozaki, M, Kim, J, Giuliano, AE et al. (2005). Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene 24: 4721-4727.
143. Wang, H, Wang, XQ, Xu, XP and Lin, GW (2010). ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leuk Res 34: 598-604.
144. Yuen, HF, Chua, CW, Chan, YP, Wong, YC, Wang, X and Chan, KW (2006). Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Mod Pathol 19: 931-941.